Nachrichten zur Swedish Orphan Biovitrum AB Aktie

Rare Strength Powers Growth - Sobi Capital Markets Day 2019

STOCKHOLM , May 14, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q1 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum AB (publ) 2019 Q1 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sobi Publishes 2018 Annual and Sustainability Report

STOCKHOLM , April 18, 2019 /PRNewswire/ - Swedish Orphan Biovitrum AB (publ)…

Invitation to Sobi Capital Markets Day 14 May 2019

STOCKHOLM , Feb. 21, 2019 /PRNewswire/ -- Save the date for Swedish…

Swedish Orphan Biovitrum AB 2018 Q4 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca completes sale of respiratory tract treatment to Sobi for $1.6bn

AstraZeneca said it had completed an agreement to sell the US rights to lower respiratory tract infection treatment Synagis to…

Sobi Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares

STOCKHOLM , Jan. 24, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

FDA Approves Gamifant® (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)

STOCKHOLM , Nov 20, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Swedish Orphan Biovitrum Acquires Synagis U.S. Rights

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum ABs (BIOVF) CEO Guido Oelkers on Merger & Acquisition Conference - Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astrazeneca verkauft US-Rechte an Synagis für 1,5 Mrd US-Dollar

Von Carlo Martuscelli FRANKFURT (Dow Jones)--Der Pharmakonzern Astrazeneca verkauft die US-Rechte am Mittel Synagis an die Swedish Orphan Biovitrum (Sobi)…

AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront

AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a…

AstraZeneca sells US rights to respiratory tract infection treatment

AstraZeneca said Tuesday it had agreed to sell the US rights to its respiratory tract infection treatment to Swedish Orphan…

Sobi to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth

STOCKHOLM , Nov. 13, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q3 2018 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum AB 2018 Q3 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sobi Completes Acquisition of the Global Rights for Emapalumab From Novimmune

STOCKHOLM , August 23, 2018 /PRNewswire/ -- Following approvals from relevant competition authorities, …

First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

STOCKHOLM , Aug.10, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) announces that…

Swedish Orphan Biovitrum AB ADR 2018 Q2 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Gene Therapy for Mucopolysaccharidosis Pipeline Analysis Report 2018 Featuring Sangamo Therapeutics, Swedish Orphan Biovitrum & uniQure

DUBLIN, June 15, 2018 /PRNewswire/ -- The "Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report" report…

Swedish Orphan Biovitrum AB ADR 2017 Q4 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kineret® (anakinra) Receives a Positive Opinion from CHMP for the Treatment of Stills Disease

STOCKHOLM, Feb. 23, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the Committee for Medicinal Products…

Sobis metabolic disorder drug secures fast track status in US

The US Food and Drug Administration (FDA) has accepted Swedish Orphan Biovitrums (Sobi) new drug application and granted fast track…

FDA Accepts Investigational New Drug Application and Grants Fast Track Status for SOBI003 for the Treatment of MPS IIIA

STOCKHOLM, Jan. 23, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) announces that the FDA has…

Sobi - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Stills Disease

STOCKHOLM, Nov. 16, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) announces that the first patient…

Swedish Orphan Biovitrum AB ADR 2017 Q3 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sobi: Alprolix® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B

STOCKHOLM, Oct. 25, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the Saudi Food & Drug…

Sobi Establishes New Leadership Structure and Appoints Torbjörn Hallberg as General Counsel

STOCKHOLM, Oct. 24, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces the establishment of…

Norbert Oppitz Joins Sobi as New Senior Vice President, Specialty Care

STOCKHOLM, Oct. 6, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that Norbert Oppitz has been appointed…

EMA Approves the Potential to Dose Every 14 Days or Longer in Updated Dosing Regimen for Alprolix®

STOCKHOLM, June 27, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) has received approval from the European Medicines Agency…

Sobi Discloses Payments to the Healthcare Professionals and Healthcare Organisations to Increase Transparency

STOCKHOLM, May 31, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the company has made all…

Swedish Orphan Biovitrum AB - Elocta® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia A

STOCKHOLM, May 18, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the Saudi…

Swedish Orphan Biovitrum AB - Orfadin® Capsules Approved in the Kingdom of Saudi Arabia for the Treatment of Hereditary Tyrosinemia Type 1

STOCKHOLM, May 17, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the Saudi…

Guido Oelkers Appointed President and CEO at Sobi

STOCKHOLM, May 04, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that Guido Oelkers…

Swedish Orphan Biovitrum AB - FDA Approves in-use Storage at Room Temperature for Orfadin® Capsules

STOCKHOLM, Mar 07, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that FDA has…

Sobi Receives Approval From the European Medicines Agency for Higher capacity Drug Substance Manufacturing for Elocta®

STOCKHOLM, Mar 02, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) has received approval from…

Swedish Orphan Biovitrum Partnering Deals and Alliances 2010 to 2017

LONDON, Feb. 27, 2017 /PRNewswire/ -- This report provides all the information you require to better understand Swedish Orphan Biovitrum…

Sobi Enters Into new Distribution Agreement With Valeant for Ammonul®

STOCKHOLM, Feb 21, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the company…

B6E: WIEDERAUFNAHME/RESUMPTION

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

ZERTIFIKATEBOERSE RESUMPTION OF UNDERL.: SE0000872095

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING SE0000872095 SIND AB 15:03 CET WIEDER IN DEN HANDEL AUFGENOMMEN. ALL STRUCTURED PRODUCTS WITH UNDERLYING SE0000872095…

ZERTIFIKATEBOERSE SUSPENSION OF UNDERL.: SE0000872095

ALLE STRUKTURIERTEN PRODUKTE MIT UNDERLYING SE0000872095 SIND AB SOFORT VOM HANDEL AUSGESETZT BIS AUF WEITERES. ALL STRUCTURED PRODUCTS WITH UNDERLYING SE0000872095…

B6E: AUSSETZUNG/SUSPENSION

DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT: THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

BRIEF-Swedish Orphan Biovitrum-long-term safety, efficacy data of extended half-life therapy Alprolix in children published

* Swedish Orphan Biovitrum - long-term safety, efficacy data of extended half-life therapy alprolix in children with hemophilia B published in Lancet…

Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy Alprolix in Children With Haemophilia B Published in The Lancet Haematology

STOCKHOLM, Feb 02, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Bioverativ Inc. (NASDAQ: BIVVV) today…